Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2022 Earnings Conference Call August 4, 2022 4:30 AM ET

Company Participants

Diane Weiser - SVP, Corporate Communications and Investor Relations

Robert Blum - President And Chief Executive Officer

Fady Malik - EVP, Research and Development

Andrew Callos - EVP, Chief Commercial Officer

Stuart Kupfer - SVP, Chief Medical Officer

Robert Wong - VP, Chief Accounting Officer

Ching Jaw - SVP, Chief Financial Officer

Conference Call Participants

Justin Kim - Oppenheimer

Yasmeen Rahimi - Piper Sandler

Michael Linden - Mizuho Group

Joseph Pantginis - H.C. Wainwright

Jason Butler - JMP Securities

Charles Duncan - Cantor

Rohit Bhasin - Needham & Company

Operator

Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Second Quarter 2022 Conference Call. At this time, I would like to inform you that this call is being recorded. All participants are in a listen-only mode. [Operator Instructions].

I would now like to turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser

Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with a brief overview of the quarter and recent developments. Fady Malik, EVP of R&D, will provide updates related to omecamtiv mecarbil and aficamten. Andrew Callos, EVP and Chief Commercial Officer, will discuss commercialization planning activities for omecamtiv mecarbil and our specialty cardiology franchise strategy related to aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will provide an update on reldesemtiv. Robert Wong, VP and Chief Accounting Officer, will provide a financial overview for the past quarter. And Ching Jaw, SVP and Chief Financial Officer, will discuss our financial outlook and revised 2022 guidance. Finally, Robert Blum will provide closing comments and will review expected upcoming milestones.

Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our second quarter 2022 financial results filed on Form 8-K today. We undertake no obligation to update any forward-looking statements after this call.

And now I will turn the call over to Robert.